BMC BioinformaticsBioinformaticsPeer-reviewed journal article
Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
Belinda B. GaranaiD, James H. JolyiD, Alireza DelfarahiD, Hyunjun Hong, Nicholas Alexander GrahamiD
Abstract
BACKGROUNDThere is a pressing need for improved methods to identify effective therapeutics for disease. Many computational approaches have been developed to repurpose existing drugs to meet this need. However, these tools often output long lists of candidate drugs that are difficult to interpret, and individual drug candidates may suffer from unknown off-target effects. We reasoned that an approach which aggregates information from multiple drugs that share a common mechanism of action (MOA) would increase on-target signal compared to evaluating drugs on an individual basis. In this study, we present Drug Mechanism Enrichment Analysis (DMEA), an adaptation of Gene Set Enrichment Analysis (GSEA), which groups drugs with shared MOAs to improve the prioritization of drug repurposing candidates. RESULTSFirst, we tested DMEA on simulated data and showed that it can sensitively and robustly identify an enriched drug MOA. Next, we used DMEA on three types of rank-ordered drug lists: (1) perturbagen signatures based on gene expression data, (2) drug sensitivity scores based on high-throughput cancer cell line screening, and (3) molecular classification scores of intrinsic and acquired drug resistance. In each case, DMEA detected the expected MOA as well as other relevant MOAs. Furthermore, the rankings of MOAs generated by DMEA were better than the original single-drug rankings in all tested data sets. Finally, in a drug discovery experiment, we identified potential senescence-inducing and senolytic drug MOAs for primary human mammary epithelial cells and then experimentally validated the senolytic effects of EGFR inhibitors. CONCLUSIONSDMEA is a fast and versatile bioinformatic tool that can improve the prioritization of candidates for drug repurposing. By grouping drugs with a shared MOA, DMEA increases on-target signal and reduces off-target effects compared to analysis of individual drugs. DMEA is publicly available as both a web application and an R package at https://belindabgarana.github.io/DMEA.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 12
- FWCI
- 1.71
- Field percentile
- top 15%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Drug Repurposing Encyclopedia (DRE): a web server for systematic drug repurposing across 20 organisms
Xuexin Li, Lu Pan, … Óscar Fernández-Capetillo·bioRxiv·Mar 10, 2023
- Design and application of a knowledge network for automatic prioritization of drug mechanisms
Michael Mayers, Roger Tu, … Andrew I. Su·BioinformaticsPeer-reviewed·Apr 6, 2022
- A gene essentiality signature enables predicting the mechanism of action of drugs
Wenyu Wang, Jie Bao, … Jing Ping Tang·bioRxiv·Nov 7, 2022
- DrugRepo: A novel approach to repurpose a huge collection of compounds based on chemical and genomic features
Yinyin Wang, Jehad Aldahdooh, … Ziaurrehman Tanoli·bioRxiv·Apr 21, 2022
- Deep characterization of cancer drugs mechanism of action by integrating large-scale genetic and drug screens
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies
Susanna Savander, Nurettin Nusret Curabaz, … Ziaurrehman Tanoli·Briefings in BioinformaticsPeer-reviewed·Nov 1, 2025